Torray Investment Partners LLC Increases Stock Holdings in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

Torray Investment Partners LLC increased its position in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) by 66.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 122,095 shares of the biotechnology company's stock after purchasing an additional 48,671 shares during the quarter. Torray Investment Partners LLC owned 0.13% of Rocket Pharmaceuticals worth $1,535,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Wellington Management Group LLP grew its holdings in shares of Rocket Pharmaceuticals by 22.8% during the 3rd quarter. Wellington Management Group LLP now owns 11,242,144 shares of the biotechnology company's stock valued at $207,642,000 after purchasing an additional 2,086,424 shares during the last quarter. State Street Corp grew its stake in shares of Rocket Pharmaceuticals by 11.6% during the third quarter. State Street Corp now owns 3,102,022 shares of the biotechnology company's stock worth $57,294,000 after buying an additional 322,156 shares during the last quarter. Maverick Capital Ltd. increased its holdings in shares of Rocket Pharmaceuticals by 4.8% during the third quarter. Maverick Capital Ltd. now owns 4,118,672 shares of the biotechnology company's stock worth $76,072,000 after buying an additional 190,360 shares in the last quarter. Westfield Capital Management Co. LP lifted its stake in shares of Rocket Pharmaceuticals by 3.8% in the 3rd quarter. Westfield Capital Management Co. LP now owns 4,493,833 shares of the biotechnology company's stock valued at $83,001,000 after acquiring an additional 165,911 shares during the last quarter. Finally, Sovran Advisors LLC acquired a new stake in shares of Rocket Pharmaceuticals during the 4th quarter valued at $1,895,000. 98.39% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Analysts Set New Price Targets

Several equities analysts have commented on RCKT shares. Needham & Company LLC dropped their target price on Rocket Pharmaceuticals from $52.00 to $42.00 and set a "buy" rating for the company in a research report on Friday, February 28th. Leerink Partners dropped their price objective on shares of Rocket Pharmaceuticals from $46.00 to $44.00 and set an "outperform" rating for the company in a report on Tuesday, November 19th. Canaccord Genuity Group reduced their target price on shares of Rocket Pharmaceuticals from $39.00 to $36.00 and set a "buy" rating on the stock in a report on Monday. The Goldman Sachs Group dropped their price target on shares of Rocket Pharmaceuticals from $29.00 to $15.00 and set a "neutral" rating for the company in a research note on Monday. Finally, Jefferies Financial Group began coverage on shares of Rocket Pharmaceuticals in a research note on Wednesday, December 18th. They issued a "buy" rating and a $29.00 price objective on the stock. One investment analyst has rated the stock with a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $42.30.

Rocket Pharmaceuticals Trading Down 2.4 %

RCKT traded down $0.22 during trading on Friday, hitting $8.77. The company's stock had a trading volume of 1,080,976 shares, compared to its average volume of 1,443,365. The firm has a market capitalization of $799.45 million, a P/E ratio of -3.19 and a beta of 0.98. Rocket Pharmaceuticals, Inc. has a twelve month low of $8.25 and a twelve month high of $28.73. The stock's fifty day moving average price is $10.67 and its 200-day moving average price is $14.45. The company has a quick ratio of 6.05, a current ratio of 6.05 and a debt-to-equity ratio of 0.06.

Rocket Pharmaceuticals (NASDAQ:RCKT - Get Free Report) last posted its quarterly earnings results on Monday, March 3rd. The biotechnology company reported ($0.62) EPS for the quarter, topping analysts' consensus estimates of ($0.68) by $0.06. Analysts anticipate that Rocket Pharmaceuticals, Inc. will post -2.83 EPS for the current year.

Rocket Pharmaceuticals Profile

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.